{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:09:30Z","timestamp":1789560570314,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["EKEA-66"],"award-info":[{"award-number":["EKEA-66"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare immune response evaluation criteria in solid tumors (iRECIST) and response evaluation criteria in solid tumors (RECIST) 1.1 for response assessment of immune checkpoint inhibitor (ICI) therapy in a real-world setting in patients with melanoma and non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two-hundred fifty-two patients with melanoma and NSCLC who received CTLA-4 inhibitor ipilimumab or PD-1 inhibitors nivolumab or pembrolizumab and who underwent staging CT of the chest and abdomen were retrospectively included. Treatment response evaluation according to the RECIST 1.1 and iRECIST guidelines was performed for all patients. Response patterns, as well as overall response rate (ORR), disease control rate (DCR), and time to progression (TTP), were compared between RECIST 1.1 and iRECIST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 143 patients with progressive disease (PD) according to RECIST 1.1, 48 (33.6%) did not attain confirmation of progression (iCPD) as per iRECIST and six patients who were treated beyond RECIST 1.1 progression reached PD at a later point in time in iRECIST, resulting in a significant difference in TTP between iRECIST and RECIST 1.1 (618.3\u2009\u00b1\u2009626.9 days vs. 538.1\u2009\u00b1\u2009617.9 days, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05)). The number of non-responders as per RECIST 1.1 was 79, whereas it was 60 when using iRECIST. ORR was 28.5% for RECIST 1.1 and 34.1% for iRECIST, and corresponding DCR of 67.4% for RECIST 1.1 and 74.6% for iRECIST.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>iRECIST was more suitable than RECIST 1.1 for capturing atypical response patterns to ICI therapy in patients with melanoma and NSCLC, resulting in differences in the assessment of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical relevance statement<\/jats:title>\n                    <jats:p>Compared to RECIST 1.1, iRECIST may improve patient care and treatment decisions for patients with NSCLC or melanoma who are treated with immune checkpoint inhibitors in clinical routine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>RECIST 1.1 may incorrectly assess atypical treatment patterns to immune checkpoint inhibitors.<\/jats:italic>\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>iRECIST better captured atypical response patterns compared to RECIST 1.1.<\/jats:italic>\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>iRECIST was more suitable for assessing response to immune checkpoint inhibitors in non-small cell lung carcinoma and melanoma.<\/jats:italic>\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-024-11060-4","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:01:43Z","timestamp":1726671703000},"page":"2084-2093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Christian","family":"Nelles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Gr\u00e4f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Persigehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Gro\u00dfe Hokamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zopfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kreuzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3254-4809","authenticated-orcid":false,"given":"Simon","family":"Lennartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"11060_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6:8. https:\/\/doi.org\/10.1186\/s40425-018-0316-z","journal-title":"J Immunother Cancer"},{"key":"11060_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"11060_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"11060_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"11060_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman E, Kanjanapan Y, Champiat S et al (2019) Novel patterns of response under immunotherapy. Ann Oncol 30:385\u2013396. https:\/\/doi.org\/10.1093\/annonc\/mdz003","journal-title":"Ann Oncol"},{"key":"11060_CR6","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu W-J, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510\u20131517. https:\/\/doi.org\/10.1200\/JCO.2015.64.0391","journal-title":"J Clin Oncol"},{"key":"11060_CR7","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541\u20133543. https:\/\/doi.org\/10.1200\/JCO.2015.61.6870","journal-title":"J Clin Oncol"},{"key":"11060_CR8","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1624","journal-title":"Clin Cancer Res"},{"key":"11060_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"11060_CR10","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1158\/0008-5472.CAN-12-0733","volume":"72","author":"AT Fojo","year":"2012","unstructured":"Fojo AT, Noonan A (2012) Why RECIST works and why it should stay\u2013counterpoint. Cancer Res 72:5151\u20135157. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0733","journal-title":"Cancer Res"},{"key":"11060_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ejca.2013.10.011","volume":"50","author":"Y Liu","year":"2014","unstructured":"Liu Y, Liti\u00e8re S, de Vries EG et al (2014) The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer 50:260\u2013266. https:\/\/doi.org\/10.1016\/j.ejca.2013.10.011","journal-title":"Eur J Cancer"},{"key":"11060_CR12","doi-asserted-by":"publisher","first-page":"iv369","DOI":"10.1093\/annonc\/mdu342.23","volume":"25","author":"O Bohnsack","year":"2014","unstructured":"Bohnsack O, Hoos A, Ludajic K (2014) Adaptation of the immune related response criteria: irrecist. Ann Oncol 25:iv369. https:\/\/doi.org\/10.1093\/annonc\/mdu342.23","journal-title":"Ann Oncol"},{"key":"11060_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","volume":"20","author":"T Persigehl","year":"2020","unstructured":"Persigehl T, Lennartz S, Schwartz LH (2020) iRECIST: how to do it. Cancer Imaging 20:2. https:\/\/doi.org\/10.1186\/s40644-019-0281-x","journal-title":"Cancer Imaging"},{"key":"11060_CR14","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"11060_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/cancers13010120","volume":"13","author":"HJ Park","year":"2021","unstructured":"Park HJ, Kim GH, Kim KW et al (2021) Comparison of RECIST 1.1 and iRECIST in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 13:120. https:\/\/doi.org\/10.3390\/cancers13010120","journal-title":"Cancers (Basel)"},{"key":"11060_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00330-020-07249-y","volume":"31","author":"FS Ahmed","year":"2021","unstructured":"Ahmed FS, Dercle L, Goldmacher GV et al (2021) Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. Eur Radiol 31:1853\u20131862. https:\/\/doi.org\/10.1007\/s00330-020-07249-y","journal-title":"Eur Radiol"},{"key":"11060_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/bju.15176","volume":"127","author":"W Fukuokaya","year":"2021","unstructured":"Fukuokaya W, Kimura T, Yanagisawa T et al (2021) Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. BJU Int 127:90\u201395. https:\/\/doi.org\/10.1111\/bju.15176","journal-title":"BJU Int"},{"key":"11060_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J et al (2018) Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 88:38\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.017","journal-title":"Eur J Cancer"},{"key":"11060_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3348\/kjr.2020.0404","volume":"22","author":"B Zheng","year":"2021","unstructured":"Zheng B, Shin JH, Li H et al (2021) Comparison of radiological tumor response based on iRECIST and RECIST 1.1 in metastatic clear-cell renal cell carcinoma patients treated with programmed cell death-1 inhibitor therapy. Korean J Radiol 22:366\u2013375. https:\/\/doi.org\/10.3348\/kjr.2020.0404","journal-title":"Korean J Radiol"},{"key":"11060_CR20","unstructured":"R Core Team (2023) R: A language and environment for statistical computing. https:\/\/www.R-project.org\/"},{"key":"11060_CR21","unstructured":"RStudio Team (2020) RStudio: Integrated development for R. http:\/\/www.rstudio.com\/"},{"key":"11060_CR22","doi-asserted-by":"publisher","first-page":"e16417","DOI":"10.1097\/MD.0000000000016417","volume":"98","author":"K Amrane","year":"2019","unstructured":"Amrane K, Le Goupil D, Quere G et al (2019) Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET\/CT in patients with melanoma. Medicine (Baltimore) 98:e16417. https:\/\/doi.org\/10.1097\/MD.0000000000016417","journal-title":"Medicine (Baltimore)"},{"key":"11060_CR23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/1759-7714.13367","volume":"11","author":"H Liang","year":"2020","unstructured":"Liang H, Xu Y, Chen M et al (2020) Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: comparison of the RECIST 1.1 and iRECIST criteria. Thorac Cancer 11:1068\u20131075. https:\/\/doi.org\/10.1111\/1759-7714.13367","journal-title":"Thorac Cancer"},{"key":"11060_CR24","doi-asserted-by":"publisher","first-page":"e000146","DOI":"10.1136\/jitc-2019-000146","volume":"8","author":"F Mulkey","year":"2020","unstructured":"Mulkey F, Theoret MR, Keegan P et al (2020) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. J Immunother Cancer 8:e000146. https:\/\/doi.org\/10.1136\/jitc-2019-000146","journal-title":"J Immunother Cancer"},{"key":"11060_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/RLU.0000000000002603","volume":"44","author":"L Beer","year":"2019","unstructured":"Beer L, Hochmair M, Haug AR et al (2019) Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1\/PD-L1 blockade therapy in patients with non-small cell lung cancer. Clin Nucl Med 44:535\u2013543. https:\/\/doi.org\/10.1097\/RLU.0000000000002603","journal-title":"Clin Nucl Med"},{"key":"11060_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jtho.2018.04.010","volume":"13","author":"SI Katz","year":"2018","unstructured":"Katz SI, Hammer M, Bagley SJ et al (2018) Radiologic pseudoprogression during Anti-PD-1 therapy for advanced non-small cell lung cancer. J Thorac Oncol 13:978\u2013986. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.010","journal-title":"J Thorac Oncol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11060-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:27:15Z","timestamp":1742189235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11060-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["11060"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11060-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Simon Lennartz.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: Nils Gro\u00dfe Hokamp: Research support from Philips Healthcare; speakers bureau of Philips Healthcare and Amboss GmbH; Consultant to Bristol-Myers Squibb and BeiGene, David Zopfs: Research support from Philips Healthcare, J\u00fcrgen Wolf: Has received payments or honoraria, has received support for attendings meetings and travel, and has participated in a Data Safety Monitoring Board or Advisory Board, from Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer-Ingelheim, Chugai, Daiichi Sankyo, Janssen, Lilly, Loxo, Merck, Mirati, MSD, Novartis, Nuvalent, Pfizer, Pierre-Fabre, Roche, Seattle Genetics, Takeda, and Turning Point, Paul Br\u00f6ckelmann: Grants (institutional) from BeiGene, Bristol-Myers Squibb, Merck Sharp and Dohme, and Takeda; consulting fees from Takeda; honoraria from BeiGene, Merck Sharp and Dohme, and Takeda; travel\/meeting support from Celgene, Simon Lennartz: Authorship and speaker fees, Amboss GmbH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}